Key result
Staged percutaneous intervention for combined AS and MR is feasible in selected high-risk patients.
Why the study?
There were no formal reports of percutaneous treatment of both aortic stenosis and mitral regurgitation in the same patient.
Supports staged percutaneous dual-valve therapy only in highly selected high-risk patients; leaves open durability, selection criteria, and need for prospective trials.
Transcatheter valve therapy is becoming an established treatment for aortic stenosis (AS) and it is very promising for mitral regurgitation (MR). There are no formal reports of percutaneous treatment of both AS and MR in the same patient. Here, we report on the first human cases of successful totally percutaneous management of combined severe AS and MR as a planned staged approach and using MitraClip(®) implantation as a procedure necessitated by an unpredictable complication of self-expanding CoreValve device, respectively.
No takes yet. Share an insight, caveat, or question.
Barbanti et al. (2011) conducted a review in Severe aortic stenosis and concomitant mitral regurgitation. Staged percutaneous treatment (TAVR and TEER/TMVR) vs. Surgical double-valve replacement or isolated TAVR was evaluated. Staged percutaneous procedures for combined severe aortic stenosis and mitral regurgitation are technically feasible and best reserved for highly selected, symptomatic high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: